Multidisciplinary management of pediatric malignant rhabdoid tumor based on 5 years of experience at a tertiary care center
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Dec 2022 · 1 min read
In brief
In brief
This retrospective study of 18 pediatric malignant rhabdoid tumor patients over 5 years demonstrates that complete surgical resection is the primary predictor of survival, with 3-year overall survival of 67%. Adjuvant chemotherapy and radiotherapy improved disease control rates, supporting a multimodal treatment approach for this rare and aggressive pediatric malignancy.
Written by the GCMD Library team from the article.
Abstract
Objective
Malignant rhabdoid tumor (MRT) is a highly aggressive tumor that occurs mostly in young children with extremely poor prognosis. Standardized and effective treatment strategies for MRT have yet to be established because of its rarity. Here, we report our single-institutional experience involving MRT treatment.
Methods
Patients with newly diagnosed MRT between March 2016 and October 2021 were included. The clinical characteristic, treatment-related toxicities, clinical outcomes, and prognostic factor were retrospectively analyzed.
Results
A total of 18 patients with MRT were enrolled during the 5 years. The median age was 42.8 months (range 10 to 82 years). Among the 18 patients, 9 patients died after a median of follow-up 26 months (range 3 to 42 months). The 1-year event-free survival (EFS) and 3-year overall survival (OS) rates of the entire cohort were 63% (95% CI 46% to 74%) and 67% (95% CI 49% to 82%), respectively. Univariate analysis of patients who underwent gross or total resection followed by adjuvant chemotherapy and radiotherapy demonstrated an improvement in 1-year EFS. However, only gross resection and total resection predicted a better 3-year OS.
Conclusions
Surgical excision is still the mainstream treatment for MRT. Postoperative adjuvant treatments including chemotherapy and radiotherapy contribute to improved disease control rate. Our single-institute experience may provide insights into the multimodal treatment of MRT.